期刊
FUTURE ONCOLOGY
卷 6, 期 1, 页码 37-53出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon.09.144
关键词
alternative splicing; biomarkers; EGFR; ELISA; HER4; shedding; therapeutic antibodies; tumor growth
类别
Antibodies targeting the extracellular domains of ErbB receptors have been extensively studied for cancer drug development. This work has led to clinical approval of monoclonal antibodies against the well-known oncogenes EGFR and ErbB2. Here we discuss the biological activities of ErbB4, a less-studied member of the EGFR/ErbB growth factor receptor family and speculate on the potential clinical relevance of antibodies targeting ErbB4. In addition to their significance as therapeutics, the role of ErbB4 antibodies in prognostic and predictive applications is surveyed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据